Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 42Neoplasms 14Carcinoma, Hepatocellular 9Gastrointestinal Stromal Tumors 7Liver Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Lung Neoplasms 2Glioblastoma 2Esophageal Squamous Cell Carcinoma 2Astrocytoma 2Advanced Cancer 2Wilms Tumor 1Uterine Cervical Neoplasms 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Solid Malignant Tumors 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Physician Education 1Pancreatic Neoplasms 1Neuroblastoma 1Melanoma 1

Interventions

regorafenib 1Paclitaxel 1Everolimus 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Unresectable Locally Advanced or Metastatic Solid Tumors × regorafenib × Clear all
NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Shanghai Runshi Pharmaceutical Technology Co., Ltd

Phase 1/2 Not yet recruiting
380 enrolled
Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡